Laryngeal Cancer

Gynecological cancer risk factors.

Laryngeal cancer is considered one of the most common types of head and neck cancers and is a malignant tumor that develops in the tissues of the larynx. Alfa Cytology is a world leader in head and neck cancer research. With our extensive experience and advanced platform, we can provide the best services for laryngeal cancer.

Introduction to Laryngeal Cancer

According to the World Health Organization (WHO), over 157,000 new cases of laryngeal cancer were reported globally in 2020. It is more common among developing countries and men.

Gynecological cancer risk factors.

Pathogenesis

The main pathogenesis of laryngeal cancer involves the following.

Genetic mutations
Smoking
Alcohol consumption

Long-term exposure to these substances can lead to DNA damage and genetic changes, promoting the development of laryngeal cancer cells.

Gynecological cancer risk factors.

Relevant Targets

Laryngeal cancer research focuses on specific molecules and pathways involved in cancer development.

Epidermal growth factor receptor (EGFR)
Vascular endothelial growth factor (VEGF)
Immune checkpoint protein PD-1/PD-L1

We are exploring the potential of these goals in cancer therapy.

Novel Therapy for Laryngeal Cancer

The above information about the pathogenesis and target is crucial for effective laryngeal cancer therapy, especially targeted therapy and immunotherapy. Recently, antineoplastic agents used to treat laryngeal cancer include cisplatin, fluorouracil, capecitabine, bleomycin, carboplatin, paclitaxel, and gemcitabine. Some medicines have potential side effects, meaning safer medicines or therapies are needed.

Total laryngectomy and laryngeal preservation strategy for locally progressive laryngeal cancer. Fig.1 Total laryngectomy and larynx preservation strategies with locally advanced laryngeal (T3–4) cancer. TL: total laryngectomy; LP: larynx preservation; RT: radiotherapy; CT: chemotherapy; CRT: concurrent chemoradiotherapy. (Bozec, A., et al., 2020)

Innovations in laryngeal cancer product lines have led pharmaceutical companies to develop several different types of biologics. AstraZeneca's monalizumab met the efficacy endpoint in a Phase II clinical trial involving patients with head and neck cancer and refractory, relapsed, or treatable chronic lymphocytic leukemia, demonstrating its antitumor activity.

Fusion Protein
Monoclonal Antibody

Our Services

Some emerging therapies for laryngeal cancer under study include gene therapy, virus therapy, and combination therapy targeting multiple signaling pathways. Alfa Cytology is working on providing one-stop solutions for laryngeal cancer.

Cancer Diagnostic Development

Cancer Modeling Services

Preclinical Research Services

Laryngeal Cancer Model Development

3D Tumor Modeling

Xenograft Model

Immuno-Oncology Tumor Models

Alfa Cytology also offers a range of animal model options specifically designed for laryngeal cancer, the species include mice, rats, zebrafish, chicks, dogs, non-human primates, and others. These models are crucial in understanding disease mechanisms, evaluating therapy outcomes, and developing new therapy strategies.

Alfa Cytology is committed to the research and study of laryngeal cancer, from immune checkpoint inhibitor development services, and cell therapy development services, to cancer drug development services, providing one-stop solutions. Our cancer experts have many years of experience in the development of the latest therapies for laryngeal cancer. If you are interested in our service, please contact us for more information.

Reference

Bozec, A., et al.; (2020) Current Role of Total Laryngectomy in the Era of Organ Preservation. Cancers, 12, 584. https://doi.org/10.3390/cancers12030584

For research use only.